Cancer cell detection device for the diagnosis of bladder cancer from urine

Publication date: Available online 7 October 2020Source: Biosensors and BioelectronicsAuthor(s): Melanie MacGregor, Hanieh Safizadeh Shirazi, Kit Man Chan, Kola Ostrikov, Kym McNicholas, Alex Jay, Michael Chong, Alexander H. Staudacher, Thomas D. Michl, Aigerim Zhalgasbaikyzy, Michael P. Brown, Moein Navvab Kashani, Adam Di Fiore, Alex Grochowski, Stephen Robb, Simon Belcher, Jordan Li, Jonathan M. Gleadle, Krasimir Vasilev
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research

Related Links:

(American Association for Cancer Research) Analysis of DNA copy number variants (CNVs) in the cells exfoliated in urine showed better sensitivity and similar specificity in detecting urothelial carcinoma compared with urine cytology
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Nature Reviews Urology, Published online: 09 October 2020; doi:10.1038/s41585-020-00386-5Cancer sequencing studies have revealed that urothelial carcinomas harbour recurrent mutations in multiple genes that control epigenetics. A major challenge for basic and clinical researchers is to convert this genetic information into biological and pathological insights, as well as to tailor novel therapeutic modalities for individual patients with bladder cancer.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research
Conditions:   Metastatic Bladder Urothelial Carcinoma;   Refractory Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8 Interventions:   Drug: Docetaxel;   Drug: Eribulin Mesylate;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Bladder Cancer;   Urothelial Carcinoma Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsor:   Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Bladder Urothelial Carcinoma;   Refractory Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8 Interventions:   Drug: Docetaxel;   Drug: Eribulin Mesylate;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Bladder Cancer Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsor:   Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Successfully develop a green, facile, cost ‐effective, and reliable deposition method of 2D MXNSs onto conductive electrodes within 3 min via electroplating technique (termed electroMXenition). Under constant potential, the redox reaction in the colloidal MXNS solution generates an electric field, which drives the nanoparticles toward a s pecific electrode interface such that they are cathodically electroplated to form crystalline MXNSs. AbstractControlled deposition of 2D multilayered nanomaterials onto different electrodes to design a highly sensitive biosensing platform utilizing their active inherent electrochem...
Source: Small - Category: Nanotechnology Authors: Tags: Full Paper Source Type: research
ConclusionTAE is effective and safe to control intractable hematuria from bladder origin in cancer patients after failure of conservative management, providing effective temporary hemostasis. For bladder hemorrhage unsuitable for surgery, TAE should be considered at an early stage.Secondary abstractA literature review, followed by retrospective analysis of all patients with intractable hematuria from bladder treated by transcatheter arterial embolization at our tertiary referral center. Transcatheter arterial embolization is effective and safe to control intractable hematuria from bladder. The major complication rate and r...
Source: Japanese Journal of Radiology - Category: Radiology Source Type: research
Abstract BACKGROUND: Manual volumetric modulated arc therapy (VMAT) treatment planning for high-risk prostate cancer receiving whole pelvic radiotherapy (WPRT) with four integrated dose levels is complex and time consuming. We have investigated if the radiotherapy planning process and plan quality can be improved using a well-tuned model developed through a commercial system for knowledge-based planning (KBP). MATERIAL AND METHODS: Treatment plans from 69 patients treated for high-risk prostate cancer with manually planned VMAT were used to develop an initial KBP model (RapidPlan, RP). Prescribed doses were 5...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Poor outcomes include lower response rate to chemotherapy, higher mortality, recurrence
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Surgery, Urology, Journal, Source Type: news
More News: Biotechnology | Bladder Cancer | Cancer | Cancer & Oncology | Jordan Health | Middle East Health